Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group
- PMID: 9443459
- DOI: 10.1212/wnl.50.1.66
Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group
Abstract
We analyzed data from the 245-patient placebo group of the ALS CNTF Treatment Study Group study, a large, prospective, multicenter study of recombinant human ciliary neurotrophic factor to determine prognostic factors for length of survival in ALS. Variables examined included baseline demographic characteristics, indices of disease severity, pulmonary function, and clinical laboratory tests. Shorter survival was associated with greater age, lower percent-predicted forced vital capacity (FVC%), and lower serum chloride at study entry. A shorter interval from symptom onset to diagnosis of ALS and greater weight loss in the 2 months before study entry also predicted shortened survival times. The rate of muscle strength loss before study entry did not predict risk of mortality. Serum chloride, reflecting the degree of respiratory acidosis, was identified for the first time as being correlated with prognosis in ALS. The relationship between a patient's FVC% and the probability of survival is described.
Similar articles
-
A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group.Neurology. 1996 May;46(5):1244-9. doi: 10.1212/wnl.46.5.1244. Neurology. 1996. PMID: 8628460 Clinical Trial.
-
A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group.Ann Neurol. 1996 Feb;39(2):256-60. doi: 10.1002/ana.410390215. Ann Neurol. 1996. PMID: 8967757 Clinical Trial.
-
Comparison of slow and forced vital capacities on ability to predict survival in ALS.Amyotroph Lateral Scler Frontotemporal Degener. 2017 Nov;18(7-8):528-533. doi: 10.1080/21678421.2017.1354995. Epub 2017 Jul 25. Amyotroph Lateral Scler Frontotemporal Degener. 2017. PMID: 28741375
-
[Neurotrophic factor treatment in amyotrophic lateral sclerosis].No To Shinkei. 1998 Jul;50(7):625-30. No To Shinkei. 1998. PMID: 9739520 Review. Japanese. No abstract available.
-
Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis.Amyotroph Lateral Scler. 2008 Dec;9(6):369-74. doi: 10.1080/17482960802163614. Amyotroph Lateral Scler. 2008. PMID: 18608098 Review.
Cited by
-
Differentiation of CD133+ stem cells from amyotrophic lateral sclerosis patients into preneuron cells.Stem Cells Transl Med. 2013 Feb;2(2):129-35. doi: 10.5966/sctm.2012-0077. Epub 2013 Jan 22. Stem Cells Transl Med. 2013. PMID: 23341441 Free PMC article.
-
Amyotrophic lateral sclerosis: pathophysiology, diagnosis and management.CNS Drugs. 2011 Jan;25(1):1-15. doi: 10.2165/11586000-000000000-00000. CNS Drugs. 2011. PMID: 21128691 Review.
-
Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial.Neurotherapeutics. 2017 Jul;14(3):762-772. doi: 10.1007/s13311-016-0508-5. Neurotherapeutics. 2017. PMID: 28070747 Free PMC article. Clinical Trial.
-
Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease.Cochrane Database Syst Rev. 2017 Oct 6;10(10):CD004427. doi: 10.1002/14651858.CD004427.pub4. Cochrane Database Syst Rev. 2017. PMID: 28982219 Free PMC article.
-
Cost effectiveness of treatments for amyotrophic lateral sclerosis: a review of the literature.Pharmacoeconomics. 2002;20(6):367-87. doi: 10.2165/00019053-200220060-00002. Pharmacoeconomics. 2002. PMID: 12052096 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous